2d
Zacks.com on MSNIs it Worth Retaining QIAGEN Stock in Your Portfolio Now?QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...
7d
Zacks Investment Research on MSNQiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?A month has gone by since the last earnings report for Qiagen (QGEN). Shares have lost about 6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
Hosted on MSN1mon
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to SayQiagen (QGEN) reported $521.2 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 2.4%. EPS of $0.61 for the same period compares to $0.57 a year ago.
We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at ...
Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. This marks Qiagen’s second ...
QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on February 6 and set a price target of €42.17.
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have lost about 6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results